MetaCap

Kura Oncology (KURA) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kura Oncology (KURA) has outperformed Olema Oncology (OLMA) over the past year, losing 38.1% versus a loss of 69.7%. Over five years, KURA leads with a -50.7% price change compared with -66.4% for OLMA. Kura Oncology is the larger company by market cap ($634.9 million vs $615.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KURA-38.14%OLMA-69.70%
+61%-9%-79%
Nov 21, 20251 yearNov 20, 2026
KURA-59.33%OLMA-69.16%
+52%-23%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KURA versus OLMA key metrics
MetricKURAOLMA
Share price$6.91$7.02
Market cap$634.88M$615.00M
1-day change-5.99%-1.82%
YTD return-33.49%-71.92%
1-year return-38.14%-69.70%
5-year return-50.66%-66.36%
EPS (TTM)$-3.30$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.48M—
Revenue growth (YoY)+25.24%—
Net income (latest FY)$-278.67M$-162.45M
Operating margin-449.94%—
Net margin-412.95%—
52-week high$13.90$36.26
52-week low$6.75$6.24
Distance from 52-week high-50.29%-80.64%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+357.60%+405.70%
Average volume2.10M1.27M
Shares outstanding91.88M87.61M
Employees260131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KURA has outperformed OLMA by 31.6 percentage points over the past year.

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

KURA vs OLMA FAQ

Which is bigger, Kura Oncology or Olema Oncology?

Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $615.00M for Olema Oncology (OLMA).

Which stock has performed better over the past year, KURA or OLMA?

KURA returned -38.14% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Kura Oncology and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons